Trial Information

Summary: Evaluate a novel compound in subjects with Occluded Central Venous Access Devices.

Objective is to evaluate the safety of study drug by monitoring of adverse events and major bleeding events for up to 120 minutes following its instillation of final dose.

Several Study Inclusion Criteria Include:

• Unable to withdraw 3 mL of blood from a central venous access device.
• Hemodynamically stable

Several Study Exclusion Criteria Include:

• Inability to infuse at least 2 mL of saline through catheter
• In the opinion of investigator, subject is at "high risk" for bleeding events or embolic complications.

For more information,

If you would like to learn more about participating in this study, please send an e-mail message using the form below.